William Phillips
Cardiovascular Disease · Chesterfield, MONPI 1386755353
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,690 of the $5,747 with a category attached, or 81.6%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,413 and has fallen 78.9% since, to $508 in 2023.
Across 301 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Boehringer Ingelheim$871
- AstraZeneca$382
- United Therapeutics Corporation$313
- Regeneron Healthcare Solutions, Inc.$301
- Grifols USA, LLC$284
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,05718%
- Food & beverage$4,69082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $1,207 |
| Boehringer Ingelheim | 45 | $871 |
| AstraZeneca | 24 | $382 |
| United Therapeutics Corporation | 17 | $313 |
| Regeneron Healthcare Solutions, Inc. | 12 | $301 |
| Grifols USA, LLC | 15 | $284 |
| Actelion Pharmaceuticals US, Inc. | 20 | $248 |
| Novartis | 16 | $241 |
| Amgen | 14 | $236 |
| E.r. Squibb & Sons, L.L.C. | 14 | $227 |
| Johnson & Johnson | 14 | $227 |
| Boston Scientific | 7 | $162 |
| Mylan Specialty L.p. | 10 | $155 |
| Sanofi | 6 | $126 |
| Amarin Pharma, Inc. | 8 | $106 |
| Kowa Pharmaceuticals America, Inc. | 8 | $100 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Genentech USA, Inc. | 4 | $73 |
| Covis Pharma GmbH | 4 | $66 |
| Philips North America LLC | 3 | $59 |
| Bayer | 4 | $52 |
| Edwards Lifesciences | 2 | $41 |
| Electromed, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Gilead | 2 | $26 |
| Vapotherm Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Insmed, Inc. | 1 | $13 |
How this compares
$5,747 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Chesterfield
- James EllisonChesterfield$267K
- Glenn DavisonChesterfield$118K
- Edward HurleyChesterfield$19K
- Keith MankowitzChesterfield$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.